Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- Hiding in plain sight: Improved CAR T-cell therapy for T-cell acute lymphoblastic leukemiaon August 5, 2022 at 8:57 am
Scientists at St. Jude Children's Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed ...
- Jimi’s journey beating childhood canceron August 4, 2022 at 7:44 pm
Leg pain and lethargy prompted the Tucker family to take their son Jimi to see pediatric doctors at Arkansas Children’s (ACH) in Little Rock. Jimi was four ...
- Community 'rocks out' to raise money, remember life of boy who died from leukemiaon July 31, 2022 at 10:20 am
The toddler, who was just 18 months old at the time, fought endlessly against acute myeloid leukemia until he died in 2019.
- Blood drive Monday to honor Marshfield teen who battled leukemiaon July 30, 2022 at 4:00 am
Morgan Green was a hard-throwing pitcher at Marshfield High School before she was thrown a life-altering curveball..
- Albany’s Leukemia and Lymphoma Society gifted $5kon July 29, 2022 at 9:42 am
The Leukemia and Lymphoma Society has been awarded a $5,000 donation from The Murray Group Insurance Services, and they have a chance to double it with a little help from the local community.
- Getting more mileage from a T-cell therapy for acute myeloid leukemiaon July 29, 2022 at 7:22 am
Scientists at St. Jude Children's Research Hospital developed a strategy to improve the ability of engager (ENG) T cells to kill acute myeloid leukemia (AML). The approach showed promise in ...
- New treatment for lymphoma and leukemia arrives in Hawaiʻion July 28, 2022 at 3:35 pm
A new treatment for lymphoma and leukemia is available to Hawaiʻi children and young adults. The Chimeric Antigen Receptor T-cell therapy can be life-saving for patients with blood cancer.
- Northwestern Mutual deepens its decade-long commitment to fighting childhood cancer with $2 million donation to Alex's Lemonade Stand Foundationon July 27, 2022 at 10:16 am
Marking the 10- year anniversary of its Childhood Cancer Program, Northwestern Mutual, through its Foundation, has committed $2 million to Alex's Lemonade Stand Foundation to support the ...
- Rookie Football Star Missing NFL Season Due to Leukemia Diagnosison July 27, 2022 at 10:10 am
Standout rookie football star John Metchie III revealed that he was diagnosed with a rare form of leukemia that targets his ...
- Dairy Queen Miracle Treat Day will raise funds for Children's Miracle Network Hospitalson July 26, 2022 at 12:39 pm
Customers in Nashville can stop by a Dairy Queen on Thursday to support Children's Miracle Network Hospitals for Miracle Treat Day.
via Bing News